Login / Signup

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

Kenneth B GordonM LebwohlKim A PappH BachelezJ J WuR G LangleyAndrew BlauveltB KaplanM ShahY ZhaoR SinvhalKristian Reich
Published in: The British journal of dermatology (2021)
Risankizumab demonstrated a favourable safety profile over short- and long-term treatment in patients with moderate-to-severe psoriasis.
Keyphrases
  • clinical trial
  • high intensity
  • early onset
  • atopic dermatitis
  • randomized controlled trial
  • drug induced
  • open label